GSK reported Phase 3 results for bepirovirsen, an antisense oligonucleotide in development for chronic hepatitis B, describing a functional cure rate of 19% across two trials after discontinuation of nucleos(t)ide therapy. In the B-Well programs, 20% and 19% of patients achieved the trial’s functional cure endpoint versus none in the placebo arms. GSK reported that adverse events were common in both groups, with grade 3 or higher events more frequent with bepirovirsen and alanine aminotransferase elevations among the most common higher-grade events. The company framed the results as a step change versus standard of care, given the fixed-duration approach and the functional cure definition requiring HBsAg loss and sustained HBV DNA suppression. If confirmed through regulatory review and longer follow-up, bepirovirsen could reshape treatment expectations for chronic HBV and further accelerate investment in next-generation antivirals that aim beyond viral suppression.